Drug Profile
Research programme: anticancer therapeutics - Xantos/Cryptome
Alternative Names: Anticancer therapeutics research programme - Xantos/CryptomeLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cryptome Pharmaceuticals; Xantos Biomedicine
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Germany
- 17 Jun 2005 Preclinical trials in Cancer in Australia (unspecified route)